Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

44.6K
Overview
44.6K
Cancer Vaccines01:30

Cancer Vaccines

383
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
383

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of a policy intended to reduce vasopressin use in intensive care unit patients with shock.

Journal of critical care·2026
Same author

Characterising the circulation of gametocytes and mosquito infectivity in induced blood stage malaria.

The Journal of infectious diseases·2026
Same author

MAHRP2 is required for tether formation and cytoadherence in <i>Plasmodium falciparum</i> infected red blood cells.

Frontiers in cellular and infection microbiology·2026
Same author

A novel hookworm vaccine candidate identified through immunomic profiling of human protective immunity.

International journal for parasitology·2026
Same author

Immunotherapy of TSA-1.C4 or in combination with BNZ confers protection against Trypanosoma cruzi infection with a distinct cytokine response.

Vaccine·2026
Same author

Saved by My Specs: Incidental central retinal vein occlusion uncovering infective endocarditis - A case report.

IDCases·2026
Same journal

Vaccination policies for healthcare personnel in Europe, 2026.

Vaccine·2026
Same journal

A historical overview of the anti-vaccine movement and its public health implications.

Vaccine·2026
Same journal

Vaccine strategies and development before and during the 1968 H3N2 influenza pandemic.

Vaccine·2026
Same journal

Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.

Vaccine·2026
Same journal

V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023.

Vaccine·2026
Same journal

In silico selection and in vivo evaluation of scoloptoxin SSD14, Rm-inositol monophosphatase, and Rm-neprilysin as potential anti-tick vaccines.

Vaccine·2026
See all related articles

Related Experiment Video

Updated: Jul 12, 2025

Determining Soil-transmitted Helminth Infection Status and Physical Fitness of School-aged Children
10:57

Determining Soil-transmitted Helminth Infection Status and Physical Fitness of School-aged Children

Published on: August 22, 2012

23.5K

Vaccine value profile for Hookworm.

Karl Philipp Puchner1, Maria Elena Bottazzi2, Victoria Periago3

  • 1Policy Cures Research, Sydney, Australia.

Vaccine
|October 20, 2023
PubMed
Summary
This summary is machine-generated.

Developing a hookworm vaccine shows moderate biological and implementation feasibility. Combining a vaccine with current interventions could significantly reduce disease burden cost-effectively, offering a promising new tool against this neglected tropical disease.

Keywords:
FeasibilityHookwormVaccineValue

More Related Videos

A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model
08:38

A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model

Published on: March 3, 2023

1.4K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K

Related Experiment Videos

Last Updated: Jul 12, 2025

Determining Soil-transmitted Helminth Infection Status and Physical Fitness of School-aged Children
10:57

Determining Soil-transmitted Helminth Infection Status and Physical Fitness of School-aged Children

Published on: August 22, 2012

23.5K
A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model
08:38

A Strategy for the Study of IL-9-Producing Lymphoid Cells in the Nippostrongylus brasiliensis Infection Model

Published on: March 3, 2023

1.4K
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K

Area of Science:

  • Neglected tropical diseases research
  • Vaccine development
  • Public health interventions

Background:

  • Hookworm infection causes significant anemia, particularly in pregnant women and children in low- and middle-income countries (LMICs).
  • Existing Preventive Chemotherapy (PC) strategies have been insufficient to meet elimination targets for neglected tropical diseases (NTDs).
  • Novel interventions are crucial for advancing NTD elimination goals.

Purpose of the Study:

  • To assess the biological and implementation feasibility of developing a hookworm vaccine.
  • To evaluate the potential added value of a hookworm vaccine as a new public health tool.
  • To identify actions that could facilitate the timely development and introduction of a hookworm vaccine.

Main Methods:

  • Pipeline landscaping and analysis of host-pathogen interactions to determine biological feasibility.
  • Evaluation of manufacturing, regulatory pathways, and potential vaccine uptake for implementation feasibility.
  • Disease burden modeling to assess the impact of vaccine introduction alongside existing interventions.

Main Results:

  • Biological feasibility for a hookworm vaccine was assessed as moderate.
  • Implementation feasibility, considering manufacturing and uptake, was also found to be moderate.
  • Modeling indicated that integrating a vaccine with PC, WASH, and shoe campaigns could be cost-saving and substantially reduce disease burden.

Conclusions:

  • A hookworm vaccine presents moderate biological and implementation feasibility.
  • Vaccine introduction, alongside current interventions, shows potential for cost-saving disease burden reduction.
  • Strategic actions are recommended to enhance the likelihood of successful vaccine development and deployment.